» Articles » PMID: 37834859

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Oct 14
PMID 37834859
Authors
Affiliations
Soon will be listed here.
Abstract

Diagnosing and managing metabolic dysfunction-associated steatotic liver disease (MASLD) remains a major challenge in primary care due to lack of agreement on diagnostic tools, difficulty in identifying symptoms and determining their cause, absence of approved pharmacological treatments, and limited awareness of the disease. However, prompt diagnosis and management are critical to preventing MASLD from progressing to more severe forms of liver disease. This highlights the need to raise awareness and improve understanding of MASLD among both patients and physicians. The patient perspective is invaluable to advancing our knowledge of this disease and how to manage it, as their perspectives have led to the growing recognition that patients experience subtle symptoms and that patient-reported outcomes should be incorporated into drug development. This review and expert opinion examine MASLD and metabolic dysfunction-associated steatohepatitis from the patient and physician perspective from pre-diagnosis to diagnosis and early care, through to progression to advanced liver damage. Specifically, the paper dives into the issues patients and physicians experience, and, in turn, what is required to improve diagnosis and management, including tips and tools to empower patients and physicians dealing with MASLD.

Citing Articles

Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard.

Sheikh M, Hasan N, Almozuaghi M, Akhtar N, Grewal Y, Schneider C Diagnostics (Basel). 2025; 15(5).

PMID: 40075862 PMC: 11898527. DOI: 10.3390/diagnostics15050615.


The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus.

Parlar M, Mutlu H, Dogantekin B, Musaoglu I, Albayrakoglu N, Yavuz M Diagnostics (Basel). 2025; 15(4).

PMID: 40002577 PMC: 11854770. DOI: 10.3390/diagnostics15040426.


Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH).

Younossi Z, Stepanova M, Younossi I, Racila A JHEP Rep. 2025; 7(3):101276.

PMID: 39980748 PMC: 11835563. DOI: 10.1016/j.jhepr.2024.101276.


Hemoglobin glycation index and mortality risk in metabolic dysfunction-associated steatotic liver disease patients: a novel U-shaped association.

Zhao M, Sun N, Cheng Y, Zhang W, Ji J, Li Q Sci Rep. 2025; 15(1):1465.

PMID: 39789085 PMC: 11718243. DOI: 10.1038/s41598-024-82034-1.


A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Romero-Gomez M Liver Int. 2025; 45(2):e16224.

PMID: 39752213 PMC: 11698224. DOI: 10.1111/liv.16224.


References
1.
Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D . The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005; 4:10. PMC: 1327680. DOI: 10.1186/1476-5926-4-10. View

2.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L . Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2):367-78.e5. DOI: 10.1053/j.gastro.2015.04.005. View

3.
Shanmugam H, Di Ciaula A, Di Palo D, Molina-Molina E, Garruti G, Faienza M . Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver. Eur J Clin Invest. 2021; 51(7):e13597. PMC: 8209861. DOI: 10.1111/eci.13597. View

4.
Clark J . Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006; 40 Suppl 1:S39-43. DOI: 10.1097/01.mcg.0000168641.31321.fa. View

5.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View